(PharmaNewsWire.Com, May 12, 2017 ) Publisher's, "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors. This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Publisher's Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.
Report Scope - The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors - The report provides the marketed drugs information including its sales, development activities and details of patent expiry - The report provides the insight of current and future market for PD and PD-L1 inhibitors - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling - The report also gives the information of dormant pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to Buy - Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage - Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors - Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine. - Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics - Developing strategic initiatives to support your drug development activities. - Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business. - Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline - Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents Introduction Executive Summary Programmed Death 1 (PD-1) Programmed Death Ligand 1 (PD-L1) Role of PD-1 and PD-L1 pathways MOA of PD-1 and PD-L1 inhibitors Significance of PD-1 and PD-L1 inhibitors PD-1 and PD-L1 Active Therapy Areas & Epidemiology Metastatic Renal Cell Carcinoma Squamous Cell Carcinomas of the Head and Neck Metastatic Colorectal Cancer Non-Small Cell lung cancer Biomarkers - PD-1 and PD-L1 inhibitors Market Overview Comparative Analysis of Pipeline &Marketed Drugs Marketed Product of PD-1 and PD-L1 drugs -Overview Marketed Drug Candidate Profiles Pembrolizumab Nivolumab Atezolizumab Marketed Drugs Sales Details of Patent Expiry of Marketed Drugs Current and Future Market for PD and PD-L1 inhibitors Challenges and Barriers associated with use of PD and PD-L1 inhibitors PD-1/PD-L1Combinations Creating Boom Pipeline Therapeutics An overview of pipeline products Pipeline Therapeutics Overview Therapeutics under Development by MOA Therapeutics under Development by Companies Last Stage Products (Phase III and Filed) Comparative Analysis Mid Stage Products (Phase II) Comparative Analysis Early Stage Products (Phase I and IND) Comparative Analysis Pre-Clinical and Discovery Products Comparative Analysis Unknown Stages Molecules Therapeutic Assessment of pipeline Therapeutics under Development by Product Type Therapeutics under Development by Phase for Monotherapy Therapeutics under Development by Phase for Combination therapy Therapeutics under Development by Molecule Type Assessment by Stage and Molecule Type Therapeutics under Development by Route of Administration Assessment by Stage and Route of Administration Dormant Products Comparative Analysis SWOT Analysis
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
